Correction to "Discovery of Selenium-Containing STING Agonists as Orally Available Antitumor Agents"

Xi Feng,Lixia Pan,Zhiyu Qian,Dongyu Liu,Xin Guan,Li Feng,Bin Song,Xi Xu,Ninghua Tan,Yi Ma,Zhiyu Li,Zhe Wang,Jinlei Bian

DOI: https://doi.org/10.1021/acs.jmedchem.3c02318

IF: 8.039

2024-01-03

Journal of Medicinal Chemistry

Abstract:J Med Chem . 2023 Dec 29. doi: 10.1021/acs.jmedchem.3c02318. Online ahead of print. NO

chemistry, medicinal

What problem does this paper attempt to address?

Correction to "Discovery of Novel Acridane-Based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects"

Xiaopeng Peng,Yichang Ren,Wanyi Pan,Jin Liu,Jianjun Chen

DOI: https://doi.org/10.1021/acs.jmedchem.4c01498

IF: 8.039

2024-07-19

Journal of Medicinal Chemistry

Abstract:J Med Chem . 2024 Jul 18. doi: 10.1021/acs.jmedchem.4c01498. Online ahead of print. NO

chemistry, medicinal
Structure−Activity Relationship Study of Benzothiophene Oxobutanoic Acid Analogues Leading to Novel Stimulator of Interferon Gene (STING) Agonists

Ancheng Shen,Xiyuan Li,Yan Zhang,Jing Ma,Ruoxuan Xiao,Xiyuan Wang,Zilan Song,Zhiguo Liu,Meiyu Geng,Ao Zhang,Zuoquan Xie,Chunyong Ding

DOI: https://doi.org/10.1016/j.ejmech.2022.114627

IF: 7.088

2022-01-01

European Journal of Medicinal Chemistry

Abstract:Pharmacological activation of stimulator of interferon genes (STING) by agonists has emerged as a new modality of cancer immunotherapy. However, current available STING agonists remain in early developmental stage or failed in clinic trials due to limited efficacy in humans. In this report, we performed a structure-activity relationship study based on the benzothiophene oxobutanoic acid scaffold of MSA-2, a well-documented STING agonist by Merck, leading to a series of N-substituted acyloxyamino derivatives with potent STING activating effect. Among them, compounds 57 and 60 displayed the most potent activity specifically targeting both h- and m-STING. Particularly, 57 displayed more potent and rapid activation of the STING signaling pathway than ADU-S100 in THP1-Dual cells. In vivo anti-tumor efficacy of 57 by intratumoral or oral administration was also demonstrated in several mouse tumor models. Intriguingly, treatment with 57 eradicated all the CT26 tumor without further recurrence in all treated mice, which could also reject the same tumor re-inoculation, indicating an induction of immune memory by 57. Taken together, acyloxyamino derivative 57 represents a new chemotype of STING agonist with well-demonstrated in vivo anti-tumor activity, which is deserved for further investigation.
Correction To: Methylseleninic Acid Suppresses Breast Cancer Growth Via the JAK2/STAT3 Pathway

Tao Zhang,Xinying Zhu,Jinxia Qiu,Kangfeng Jiang,Gan Zhao,Haichong Wu,Ganzhen Deng,Changwei Qiu

DOI: https://doi.org/10.1007/s43032-020-00353-w

2020-01-01

Reproductive Sciences

Abstract:Due to an unfortunate oversight, author names have been misspelt.
Correction to "Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors"

Chunju Yang,Bang Li,Zongbo Feng,Huaxuan Li,Hong Yang,Zhenjiao Yang,Li Liu,Qiongyu Shi,Hong Wang,Zhong-Zhu Chen,Xun Huang,Junjian Wang,Yuanxiang Wang

DOI: https://doi.org/10.1021/acs.jmedchem.4c02417

IF: 8.039

2024-10-17

Journal of Medicinal Chemistry

Abstract:J Med Chem . 2024 Oct 15. doi: 10.1021/acs.jmedchem.4c02417. Online ahead of print. NO

chemistry, medicinal
Correction to "Mannosylated STING Agonist Drugamers for Dendritic Cell-Mediated Cancer Immunotherapy"

Dinh Chuong Nguyen,Kefan Song,Simbarashe Jokonya,Omeed Yazdani,Drew L Sellers,Yonghui Wang,Abm Zakaria,Suzie H Pun,Patrick S Stayton

DOI: https://doi.org/10.1021/acscentsci.4c00532

2024-04-16

Abstract:[This corrects the article DOI: 10.1021/acscentsci.3c01310.].
Discovery of Novel Thieno[2,3-d]imidazole Derivatives As Agonists of Human STING for Antitumor Immunotherapy Using Systemic Administration.

Jing Niu,Hudagula Bai,Zizhou Li,Yuzhe Gao,Yan Zhang,Xiyuan Wang,Yaxi Yang,Yungen Xu,Meiyu Geng,Zuoquan Xie,Bing Zhou

DOI: https://doi.org/10.1016/j.ejmech.2022.114482

IF: 7.088

2022-01-01

European Journal of Medicinal Chemistry

Abstract:The activation of stimulator of interferon genes (STING) signaling pathways plays an important role in the innate immune response. Although several STING agonists have been developed recently, the majority of clinical CDN STING agonists are administered by intratumoral (IT) injection. Therefore, there remains a need to develop diverse non-CDN small-molecule STING agonists with systemic administration. Herein, by using a scaffold hopping strategy, we designed a series of thieno [2,3-d]imidazole derivatives as novel STING agonists. Further structure-activity relationship study and optimization led to the discovery of compound 45 as a highly potent human STING agonist with an EC50 value of 1.2 nM. Compound 45 was found to bind to multiple human STING isoforms and accordingly activated the downstream TBK1/IRF3 and NF-κB signaling pathways in the reporter cells bearing with different STING isoforms. The activation on STING signaling pathway was abolished in the STING knock-out cells, indicating that it is a specific STING agonist. Compound 45 significantly inhibited the tumor growth in allograft 4T1 and CT26 tumor models by systemic administration, and more significantly, 45 was able to induce tumor regression in CT26 tumor model without inducing weight loss, suggesting that compound 45 is a highly promising candidate worthy for further development.
A novel STING agonist with systemic and durable anti-tumour activity

Xiyuan Wang,Ancheng Shen,Yan Zhang,Xiaoxu Chen,Jian Ding,Ao Zhang,Meiyu Geng,Chunyong Ding,Zuoquan Xie

DOI: https://doi.org/10.1002/ctd2.231

2023-01-01

Clinical and Translational Discovery

Abstract:BackgroundStimulator of interferon genes (STING) has emerged as a crucial and promising target in tumor immunotherapy in recent years. Its agonists play a vital role in activating both innate and adaptive immune responses to combat cancer. Currently, STING agonists are primarily administered through intratumoral or intravenous injection, with only a few could be administered by orally. Therefore, orally available STING agonists are urgently needed to be developed.Approach and resultsBased on previous structure-activity relationship (SAR) studies, we made a structure modification to MSA-2 by replacing the carbonyl group with a difluoromethylene to get a new compound 202 (C202) that exhibited better plasma exposure and oral bioavailability than MSA-2. Thus, we conducted extensive pharmacological evaluations to understand its effects. C202 demonstrated the ability to activate various human STING isoforms and murine STING protein, showcasing a potent and specific activation of the STING signalling pathway at cellular level. In diverse immunocompetent mouse models representing both 'cold' and 'hot' tumors, C202, whether administered intratumorally or orally, displayed broad-spectrum anti-tumor activity. Encouragingly, it induced complete tumor regression in several tumor models of mice and stimulated immune memory effects, contributing to long-term immune response against cancer. Additionally, our investigations into the impact of C202 on the tumor microenvironment found that it enhanced the anti-tumor response of both innate and adaptive immune systems, bolstering the immune-mediated fight against tumors. Furthermore, we made an intriguing observation regarding C202's synergistic effects. It was found to enhance the anti-tumor activity of chemotherapy drug gemcitabine and the angiogenesis inhibitor AL3810, which provide potential combination therapies in future translational studies.ConclusionsOur research highlights C202 as a novel STING agonist with durable anti-tumor activity that can be administered orally, presenting a promising candidate for cancer immunotherapy. C202 specifically activates various STING isoforms and its downstream signalling, and exhibited high oral bioavailability and plasma exposure and displayed broad-spectrum anti-tumor activity either by local or oral administration. C202 activated both innate and adaptive anti-tumor immunity, and importantly it induced complete tumor regression and immune memory,C202 exerts synergistic effects with chemotherapy (gemcitabine) or angiogenesis inhibitor (AL3810) in anti-tumor. # image
Correction to Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (C-Met) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(quinolin-6-ylmethyl)-1h-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1h-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer

J. Jean Cui,Michele McTigue,Mitchell D. Nambu,Michelle Tran‐Dubé,Mason Pairish,Hong Shen,Lei Jia,Hengmiao Cheng,Justin Hoffman,Phuong A. Le,Mehran Jalaie,Gilles H. Goetz,Marcel Koenig,Tomáš Vojkovský,Fangjie Zhang,Steven Do,Iriny Botrous,Kevin M. Ryan,Neil B. Grodsky,Ya‐Li Deng,Max Parker,Sergei Timofeevski,Brion W. Murray,Shinji Yamazaki,Shirley A. Aguirre,Qiuhua Li,Helen Y. Zou,James G. Christensen

DOI: https://doi.org/10.1021/jm3014647

IF: 8.039

2012-01-01

Journal of Medicinal Chemistry

Abstract:ADVERTISEMENT RETURN TO ISSUEPREVAddition/CorrectionNEXTORIGINAL ARTICLEThis notice is a correctionCorrection to Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of CancerJ. Jean Cui*, Michele McTigue, Mitchell Nambu, Michelle Tran-Dubé, Mason Pairish, Hong Shen, Lei Jia, Hengmiao Cheng, Jacqui Hoffman, Phuong Le, Mehran Jalaie, Gilles H. Goetz, Marcel Koenig, Tomas Vojkovsky, Fang-Jie Zhang, Steven Do, Iriny Botrous, Kevin Ryan, Neil Grodsky, Ya-li Deng, Max Parker, Sergei Timofeevski, Brion W. Murray, Shinji Yamazaki, Shirley Aguirre, Qiuhua Li, Helen Zou, and James ChristensenCite this: J. Med. Chem. 2012, 55, 22, 10314Publication Date (Web):October 19, 2012Publication History Published online19 October 2012Published inissue 26 November 2012https://pubs.acs.org/doi/10.1021/jm3014647https://doi.org/10.1021/jm3014647correctionACS PublicationsCopyright © 2012 American Chemical Society. This publication is available under these Terms of Use. Request reuse permissions This publication is free to access through this site. Learn MoreArticle Views1234Altmetric-Citations2LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail PDF (123 KB) Get e-Alertsclose Get e-Alerts
Antitumor Agents 288: Design, Synthesis, SAR, and Biological Studies of Novel Heteroatom-Incorporated Antofine and Cryptopleurine Analogues As Potent and Selective Antitumor Agents.

Xiaoming Yang,Qian Shi,Shuenn-Chen Yang,Chi-Yuan Chen,Sung-Liang Yu,Kenneth F. Bastow,Susan L. Morris-Natschke,Pei-Chi Wu,Chin-Yu Lai,Tian-Shung Wu,Shiow-Lin Pan,Che-Ming Teng,Jau-Chen Lin,Pan-Chyr Yang,Kuo-Hsiung Lee

DOI: https://doi.org/10.1021/jm200330s

2011-01-01

Abstract:Novel heteroatom-incorporated antofine and cryptopleurine analogues were designed, synthesized, and tested against a panel of five cancer cell lines. Two new S-13-oxo analogues (11 and 16) exhibited potent cell growth inhibition in vitro (GI(50): 9 nM and 20 nM). Interestingly, both compounds displayed improved selectivity among different cancer cell lines, in contrast to the natural products antofine and cryptopleurine. Mechanism of action (MOA) studies suggested that R-antofine promotes dysregulation of DNA replication during early S phase, while no similar effects were observed for 11 and 15 on corresponding replication initiation complexes. Compound 11 also showed greatly reduced cytotoxicity against normal cells and moderate antitumor activity against HT-29 human colorectal adenocarcinoma xenograft in mice without overt toxicity.
Correction to "Self-Stimulated Photodynamic Nanoreactor in Combination with CXCR4 Antagonists for Antileukemia Therapy''

Yan Zhang,Liang Chen,Ting Fu,Aibo Xu,Kaiqiang Li,Ke Hao,Jianxin Lyu,Zhen Wang,Fei Kong

DOI: https://doi.org/10.1021/acsami.4c08121

IF: 9.5

2024-05-31

ACS Applied Materials & Interfaces

Abstract:ACS Appl Mater Interfaces . 2024 May 30. doi: 10.1021/acsami.4c08121. Online ahead of print. NO

materials science, multidisciplinary,nanoscience & nanotechnology
Corrigendum: Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity

Qian Zhao,Shan-Shan Xiong,Can Chen,Hong-Ping Zhu,Xin Xie,Cheng Peng,Gu He,Bo Han

DOI: https://doi.org/10.3389/fonc.2023.1259550

IF: 4.7

2023-08-25

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.972372.].

oncology
Correction to "Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma"

Xiaopeng Peng,Ling Li,Jingxuan Chen,Yichang Ren,Jin Liu,Ziwen Yu,Hao Cao,Jianjun Chen

DOI: https://doi.org/10.1021/acs.jmedchem.4c02486

IF: 8.039

2024-10-20

Journal of Medicinal Chemistry

Abstract:J Med Chem . 2024 Oct 19. doi: 10.1021/acs.jmedchem.4c02486. Online ahead of print. NO

chemistry, medicinal
Selenium: the emerging element in the medicinal chemist's toolkit

Lanmeng Cui,Wei Hou,Hongtao Xu

DOI: https://doi.org/10.4155/fmc-2024-0041

2024-02-22

Future Medicinal Chemistry

Abstract:Keywords: biocompatible DNA-encoded library parallel synthesis selenium References 1. Rayman MP . Selenium and human health . Lancet 379(9822), 1256–1268 ( 2012 ).Medline CAS Google Scholar 2. Hou W, Xu H . Incorporating selenium into heterocycles and natural products-from chemical properties to pharmacological activities . J. Med. Chem. 65(6), 4436–4456 ( 2022 ).Medline CAS Google Scholar 3. Wrobel JK, Power R, Toborek M . Biological activity of selenium: revisited . IUBMB Life 68(2), 97–105 ( 2016 ).Medline CAS Google Scholar 4. Leszczynska G, Cypryk M, Gostynski B et al. C5-substituted 2-selenouridines ensure efficient base pairing with guanosine; consequences for reading the NNG-3′ synonymous mRNA codons . Int. J. Mol. Sci. 21(8), 2882 ( 2020 ).Medline CAS Google Scholar 5. Hou W, Dong H, Zhang X, Wang Y, Su L, Xu H . Selenium as an emerging versatile player in heterocycles and natural products modification . Drug Discov. Today 27(8), 2268–2277 ( 2022 ).Medline CAS Google Scholar 6. Alhasan R, Nasim MJ, Jacob C, Gaucher C . Selenoneine: a unique reactive selenium species from the blood of tuna with implications for human diseases . Curr. Pharmacol. Reports. 5(3), 163–173 ( 2019 ).CAS Google Scholar 7. Feng X, Pan L, Qian Z et al. Discovery of selenium-containing STING agonists as orally available antitumor agents . J. Med. Chem. 65(22), 15048–15065 ( 2022 ).Medline CAS Google Scholar 8. Rech TDST, Ribeiro EH, Castro ET et al. Antidepressant potential of a functionalized 3-selanyl benzo[b]furan compound in mice: focus on the serotonergic system . ACS Chem. Neurosci. 14(6), 1181–1192 ( 2023 ).Medline CAS Google Scholar 9. Deng X, Xie B, Li Q et al. Discovery of novel bicyclic phenylselenyl-containing hybrids: an orally bioavailable, potential, and multiacting class of estrogen receptor modulators against endocrine-resistant breast cancer . J. Med. Chem. 65(11), 79 -Abstract Truncated-

chemistry, medicinal
Correction to "Unleashing the Potential of Camptothecin: Exploring Innovative Strategies for Structural Modification and Therapeutic Advancements"

Zheng Chen,Maoyu Liu,Ningyu Wang,Wenjing Xiao,Jianyou Shi

DOI: https://doi.org/10.1021/acs.jmedchem.4c01106

IF: 8.039

2024-05-23

Journal of Medicinal Chemistry

Abstract:J Med Chem . 2024 May 22. doi: 10.1021/acs.jmedchem.4c01106. Online ahead of print. NO

chemistry, medicinal
Recent Advances for the Synthesis of Selenium-containing Small Molecules As Potent Antitumor Agents.

Qi Miao,Jinyi Xu,Aijun Lin,Xiaoming Wu,Liang Wu,Weijia Xie

DOI: https://doi.org/10.2174/0929867325666171129220544

IF: 4.74

2018-01-01

Current Medicinal Chemistry

Abstract:Selenium-containing small molecules have attracted considerable attention of chemical and medicinal researchers owing to their various biological activities, such as antitumor effects, cardiovascular protection, antibacterial or antiviral effects, immunoregulation and nerve protection, among which the most promising area is antineoplasm. In the past several decades, different kinds of organoselenium compounds, such as selenides, seleno(iso)cyanates, substituted selenoureas, selenious esters and Se-containing heterocycles have been reported as candidates of anti-cancer agents. Current reviews of Se-containing anticancer compounds mainly concerned about the investigation of their bioactivities, whereas, few attention has been addressed on their synthetic approaches. Herein, we summarized methodologies recently developed to synthesize organoselenium compounds with potent antineoplastic properties, which would be helpful for further design and synthesis of new bioactive Se-containing molecules with diverse structural features.
Correction: Pentacyclic spermidine alkaloids with radioprotective and anti-inflammatory activities from Orychophragmus violaceus

Zan-Xin Xu,Bin Li,Ying Tian,Min Li,Guang-Jie Zhang,Jun-Xing Dong

DOI: https://doi.org/10.1039/d2ob90013k

2022-02-23

Abstract:Correction for 'Pentacyclic spermidine alkaloids with radioprotective and anti-inflammatory activities from Orychophragmus violaceus' by Zan-Xin Xu et al., Org. Biomol. Chem., 2021, 19, 9844-9848, DOI: 10.1039/D1OB01973B.
Abstract 4475: Discovery of an Oral Tricyclic STING Agonist with Superior Pharmacokinetic Properties and Potent in Vivo Efficacy

Hong-Yi Zhao,Zhongwei Liu,Shuai Mao,Miao He,Meilin Wang,Bo Wen,Wei Gao,Duxin Sun

DOI: https://doi.org/10.1158/1538-7445.am2024-4475

IF: 11.2

2024-01-01

Cancer Research

Abstract:Abstract Stimulator of interferon genes (STING) plays a pivotal role in regulating immune microenvironment for cancer immunotherapy. However, the use of most STING agonists has been hindered by the necessity for intra-tumoral or intravenous administration, underscoring the challenge in developing an orally bioavailable STING agonist with favorable pharmacokinetic (PK) properties. In this study, we discovered oral STING agonists featuring a novel tricyclic benzo[4,5]thieno[2,3-c]pyrrole-1,3-dione scaffold, thus achieving both superior PK properties and potent in vivo efficacy. Our lead compound, ZSA-51, exhibited nanomolar cellular STING activation activity (EC50 = 100 nM) in THP1 cells, surpassing the reported oral STING agonist MSA-2 by 32-fold (EC50 = 3200 nM). Furthermore, ZSA-51 demonstrated superior PK properties with an oral bioavailability of 49%, and robust in vivo antitumor activity both in colon and pancreatic cancers model upon oral administration. Notably, ZSA-51 displayed preferential distribution to the lymph nodes and spleen, enhancing its systemic immune-stimulating effects. The specificity of ZSA-51 was further confirmed by a comparison with a negative control compound (ZSA-52NC2) that was unable to stimulate in vitro and in vivo STING activity. Molecular docking and MD simulation confirmed that the active form of ZSA-51 stably bound to STING dimer with validated hydrogen bond network. Taken together, our findings suggest ZSA-51 as a promising oral STING agonist characterized by superior PK properties and potent in vivo efficacy, holding potential for future development for cancer immunotherapy. Citation Format: Hong-Yi Zhao, Zhongwei Liu, Shuai Mao, Miao He, Meilin Wang, Bo Wen, Wei Gao, Duxin Sun. Discovery of an oral tricyclic STING agonist with superior pharmacokinetic properties and potent in vivo efficacy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4475.
Correction to Design, Synthesis, and Antitumor Evaluation of Novel Histone Deacetylase Inhibitors Equipped with a Phenylsulfonylfuroxan Module as a Nitric Oxide Donor.

weibo duan,j li,elizabeth s inks,c j chou,yuanzhi jia,xiaowen chu,xiaoling li,wen xu,yudong zhang

DOI: https://doi.org/10.1021/acs.jmedchem.5b01075

IF: 8.039

2015-01-01

Journal of Medicinal Chemistry

Abstract:ADVERTISEMENT RETURN TO ISSUEPREVAddition/CorrectionNEXTORIGINAL ARTICLEThis notice is a correctionCorrection to Design, Synthesis, and Antitumor Evaluation of Novel Histone Deacetylase Inhibitors Equipped with a Phenylsulfonylfuroxan Module as a Nitric Oxide DonorWenwen Duan, Jin Li, Elizabeth S. Inks, C. James Chou, Yuping Jia, Xiaojing Chu, Xiaoyang Li, Wenfang Xu*, and Yingjie Zhang*Cite this: J. Med. Chem. 2015, 58, 15, 6319Publication Date (Web):July 30, 2015Publication History Published online30 July 2015Published inissue 13 August 2015https://doi.org/10.1021/acs.jmedchem.5b01075Copyright © 2015 American Chemical SocietyRIGHTS & PERMISSIONSArticle Views888Altmetric-Citations3LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InReddit PDF (110 KB) Get e-Alerts Get e-Alerts
Correction to "Stable Axially Chiral Isomers of Arylnaphthalene Lignan Glycosides with Antiviral Potential Discovered from Justicia procumbens "

Yang Zhao,Chuen-Fai Ku,Xin-Ya Xu,Nga-Yi Tsang,Yu Zhu,Chen-Liang Zhao,Kang-Lun Liu,Chuang-Chuang Li,Lijun Rong,Hong-Jie Zhang

DOI: https://doi.org/10.1021/acs.joc.4c01633

2024-08-22

The Journal of Organic Chemistry

Abstract:J Org Chem . 2024 Aug 20. doi: 10.1021/acs.joc.4c01633. Online ahead of print. NO

chemistry, organic
Correction: A highly X-ray sensitive iridium prodrug for visualized tumor radiochemotherapy

Zhennan Zhao,Pan Gao,Li Ma,Tianfeng Chen

DOI: https://doi.org/10.1039/d1sc90029c

IF: 8.4

2021-01-01

Chemical Science

Abstract:Correction for ’A highly X-ray sensitive iridium prodrug for visualized tumor radiochemotherapy’ by Zhennan Zhao et al. , Chem. Sci. , 2020, 11 , 3780–3789, DOI: 10.1039/D0SC00862A

chemistry, multidisciplinary

Correction to "Discovery of Selenium-Containing STING Agonists as Orally Available Antitumor Agents"

Correction to "Discovery of Novel Acridane-Based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects"

Structure−Activity Relationship Study of Benzothiophene Oxobutanoic Acid Analogues Leading to Novel Stimulator of Interferon Gene (STING) Agonists

Correction To: Methylseleninic Acid Suppresses Breast Cancer Growth Via the JAK2/STAT3 Pathway

Correction to "Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors"

Correction to "Mannosylated STING Agonist Drugamers for Dendritic Cell-Mediated Cancer Immunotherapy"

Discovery of Novel Thieno[2,3-d]imidazole Derivatives As Agonists of Human STING for Antitumor Immunotherapy Using Systemic Administration.

A novel STING agonist with systemic and durable anti-tumour activity

Antitumor Agents 288: Design, Synthesis, SAR, and Biological Studies of Novel Heteroatom-Incorporated Antofine and Cryptopleurine Analogues As Potent and Selective Antitumor Agents.

Correction to "Self-Stimulated Photodynamic Nanoreactor in Combination with CXCR4 Antagonists for Antileukemia Therapy''

Corrigendum: Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity

Correction to "Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma"

Selenium: the emerging element in the medicinal chemist's toolkit

Correction to "Unleashing the Potential of Camptothecin: Exploring Innovative Strategies for Structural Modification and Therapeutic Advancements"

Recent Advances for the Synthesis of Selenium-containing Small Molecules As Potent Antitumor Agents.

Correction: Pentacyclic spermidine alkaloids with radioprotective and anti-inflammatory activities from Orychophragmus violaceus

Abstract 4475: Discovery of an Oral Tricyclic STING Agonist with Superior Pharmacokinetic Properties and Potent in Vivo Efficacy

Correction to Design, Synthesis, and Antitumor Evaluation of Novel Histone Deacetylase Inhibitors Equipped with a Phenylsulfonylfuroxan Module as a Nitric Oxide Donor.

Correction to "Stable Axially Chiral Isomers of Arylnaphthalene Lignan Glycosides with Antiviral Potential Discovered from Justicia procumbens "

Correction: A highly X-ray sensitive iridium prodrug for visualized tumor radiochemotherapy